Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tobacco bill passes Senate

This article was originally published in The Tan Sheet

Executive Summary

Branded and generic nicotine replacement therapy products may get quicker routes to market under an amendment to the American Jobs Creation Act of 2004 (HR 4250), which passed the Senate July 15. The amendment, introduced by Sen. Mike DeWine (R-Ohio), would allow FDA regulation of tobacco products and provide a buyout for tobacco farmers. For NRT marketers, the provision advocates the use of time-and-extent applications and other FDA fast-tracking of smoking cessation products, reflecting DeWine's earlier bill (1"The Tan Sheet" May 24, 2004, p. 9)...

You may also be interested in...

FDA tobacco regulation burns out

A provision mandating FDA regulation of tobacco products was struck from the $140 bil. American Jobs Creation Act in the Senate Oct. 6. Co-sponsor Mike DeWine (R-Ohio) called the apparent defeat of the "Youth Smoking Prevention and Public Health Protection Act" a "missed opportunity to pass one of the most important public health provisions that the Congress could ever consider." The FDA regulation bill originally passed the Senate in July (1"The Tan Sheet" July 19, 2004, In Brief)...

Senate Tobacco Bill Advocates Extended Use, New Claims For OTC NRTs

FDA is directed to consider approving extended use of OTC nicotine replacement products in legislation introduced by Sen. Mike DeWine (R-Ohio) and Edward Kennedy (D-Mass.) May 20

COVID-19 Vaccine Authorization In Adolescents Would Raise Questions Around Routine Immunizations

US FDA not planning an advisory committee for Pfizer/BioNTech’s request for authorization in 12-15-year olds at this time, but CDC’s ACIP is likely to weigh how to balance timing of COVID vaccination with administration of other immunizations generally recommended for adolescents.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts